酒精使用障碍
医学
食品药品监督管理局
无刺
药方
标签外使用
禁欲
精神科
药物治疗
医疗急救
酒
纳曲酮
药理学
化学
受体
内科学
类阿片
生物化学
作者
Barbara J. Mason,Charles J. Heyser
出处
期刊:Alcohol research
日期:2021-01-01
卷期号:41 (1)
被引量:41
标识
DOI:10.35946/arcr.v41.1.07
摘要
The misuse of alcohol in the United States continues to take a large toll on society, resulting in the deaths of about 88,000 Americans per year. Moreover, it is estimated that nearly 14.6 million Americans currently meet diagnostic criteria for current alcohol use disorder (AUD). However, very few individuals receive treatment, with an even smaller portion receiving medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of AUD, despite scientifically rigorous evidence showing the benefits of combining medication approved for treating AUD with evidence-based behavioral therapy. These benefits include higher rates of abstinence and less risk of relapse to heavy drinking, with associated improvements in medical and mental health and in quality of life. This review provides an overview of FDA-approved medications and "off-label" drugs for the treatment of AUD. The article emphasizes that AUD medical advice and prescription recommendations should come from professionals with training in the treatment of AUD and that treatment plans should consider medication in conjunction with evidence-based behavioral therapy. Finally, this review notes the limited number of medications available and the continued need for the development of new pharmacotherapies to optimize AUD recovery goals.
科研通智能强力驱动
Strongly Powered by AbleSci AI